These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26097309)

  • 1. Relationship of long-term highly active antiretroviral therapy on salivary flow rate and CD4 Count among HIV-infected patients.
    Kumar JV; Baghirath PV; Naishadham PP; Suneetha S; Suneetha L; Sreedevi P
    J Oral Maxillofac Pathol; 2015; 19(1):58-63. PubMed ID: 26097309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy on salivary flow in patients with human-immuno deficiency virus disease in Southern India.
    Pavithra S; Ranganathan K; Rao UK; Joshua E; Rooban T; Kumarasamy N
    J Oral Maxillofac Pathol; 2013 Jan; 17(1):17-22. PubMed ID: 23798824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term use of HAART on oral health status of HIV-infected subjects.
    Nittayananta W; Talungchit S; Jaruratanasirikul S; Silpapojakul K; Chayakul P; Nilmanat A; Pruphetkaew N
    J Oral Pathol Med; 2010 May; 39(5):397-406. PubMed ID: 20202089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS).
    Navazesh M; Mulligan R; Karim R; Mack WJ; Ram S; Seirawan H; Greenspan J; Greenspan D; Phelan J; Alves M;
    Oral Dis; 2009 Jan; 15(1):52-60. PubMed ID: 19017280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
    Lin AL; Johnson DA; Sims CA; Stephan KT; Yeh CK
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):318-24. PubMed ID: 16920540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral manifestations, salivary flow rates and Candida species in Thai HIV-infected patients.
    Lam-Ubol A; Rungsiyanont S; Vacharotayangul P; Sappayatosok K; Chankanka O
    J Clin Exp Dent; 2019 Feb; 11(2):e138-e145. PubMed ID: 30805118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants.
    Navazesh M; Mulligan R; Barrón Y; Redford M; Greenspan D; Alves M; Phelan J;
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jun; 95(6):693-8. PubMed ID: 12789150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study.
    Yan Y; Ren Y; Chen R; Hu J; Ji Y; Yang J; Shen J; Hu L; Pei H; Wang J; Qiu Y; Lu H; Huang L
    Virol Sin; 2018 Jun; 33(3):227-233. PubMed ID: 29654554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women.
    Navazesh M; Mulligan R; Komaroff E; Redford M; Greenspan D; Phelan J
    J Dent Res; 2000 Jul; 79(7):1502-7. PubMed ID: 11005735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
    Chitra P; Bakthavatsalam B; Palvannan T
    Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary pH and buffering capacity in early and late human immunodeficiency virus infection.
    Hegde MN; Malhotra A; Hegde ND
    Dent Res J (Isfahan); 2013 Nov; 10(6):772-6. PubMed ID: 24379866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of Th1/Th2/Th17 cytokines and human beta defensin 2 in HIV-infected patients with oral candidiasis during the first year of highly active anti-retroviral therapy.
    Yong X; Liu Z; Jiang L; Tao R; Liu W; Zhang L; Peng Y; Lin X; Huang Y
    Arch Oral Biol; 2018 Aug; 92():62-67. PubMed ID: 29753928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
    Lin AL; Johnson DA; Stephan KT; Yeh CK
    J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era.
    Nittayananta W; Chanowanna N; Jealae S; Nauntofte B; Stoltze K
    J Oral Pathol Med; 2010 Jan; 39(1):28-34. PubMed ID: 19709350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.